Titan Partners acted as sole book running manager for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMMX:
- Immix Biopharma Suspends Stock Offering Pending New Prospectus
- Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
- Immix Biopharma Announces Proposed Public Offering of Common Stock
- Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
- Immix Biopharma ‘applauds’ FDA labeling change notification for CAR-T products